Excretion of moxidectin into breast milk and pharmacokinetics in healthy lactating women

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 11, 2011, Pages 5200-5204

  Korth Bradley, Joan M ^a   Parks, Virginia ^a,d   Chalon, Stephan ^a,e   Gourley, Ian ^a   Matschke, Kyle ^a   Gossart, Sophie ^a   Bryson, Philip ^b   Fleckenstein, Lawrence ^c  

^a PFIZER INC   (United States)

^b Veeda Clinical Research   (United Kingdom)

^c UNIVERSITY OF IOWA   (United States)

^d Shire AG   (Switzerland)

^e Roche Institute for Research and Translational Medicine   (France)

Author keywords

[No Author keywords available]

Indexed keywords

MOXIDECTIN;

ABSENCE OF SIDE EFFECTS; ADULT; ADVERSE OUTCOME; ARTICLE; BLOOD ANALYSIS; BREAST MILK; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EXCRETION; DRUG SAFETY; FEMALE; FLUORESCENCE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; LACTATION; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; OUTPATIENT CARE; PRIORITY JOURNAL; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADULT; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; HUMANS; LACTATION; MACROLIDES; MILK, HUMAN; YOUNG ADULT;

EID: 80054699860     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00311-11     Document Type: Article

References (11)

1. Carceles, C. M., et al. 2001. Milk kinetics of moxidectin and doramectin in goats. Res. Vet. Sci. 70:227-231. (Pubitemid 32756485)
2. Chen, Y. C., Y. P. Hung, and L. Fleckenstein. 2002. Liquid chromatographic assay of moxidectin in human plasma for application to pharmacokinetic studies. J. Pharm. Biomed. Anal. 29:917-926. (Pubitemid 34687008)
3. Clewell, R. A., and J. M. Gearhart. 2002. Pharmacokinetics of toxic chemicals in breast milk: use of PBPK models to predict infant exposure. Environ. Health Perspect. 110:A333-A337. (Pubitemid 34661936)
4. Cotreau, M. M., et al. 2003. The antiparasitic moxidectin: safety, tolerability, and pharmacokinetics in humans. J. Clin. Pharmacol. 43:1108-1115. (Pubitemid 37174442)
5. Cox, J. L., J. M. Holden, and R. Sagovsky. 1987. Detection of postnatal depression. Development of the 10-item Edinburgh Postnatal Depression Scale. Br. J. Psychiatry 150:782-786. (Pubitemid 17082036)
6. Ilett, K. F., and J. H. Kristensen. 2005. Drug use and breastfeeding. Expert Opin. Drug Saf. 4:745-768. (Pubitemid 40946070)
7. Imperiale, F., A. Lifschitz, J. Sallovitz, G. Virkel, and C. Lanusse. 2004. Comparative depletion of ivermectin and moxidectin milk residues in dairy sheep after oral and subcutaneous administration. J. Dairy. Res. 71:427-433. (Pubitemid 39606363)
8. Korth-Bradley, J. M., et al. 2010. The effect of a high-fat breakfast on the pharmacokinetics of moxidectin in healthy male subjects. J. Clin. Pharmacol. 50:1075.
9. Lallemand, E., A. Lespine, M. Alvinerie, A. Bousquet-Melou, and P. L. Toutain. 2007. Estimation of absolute oral bioavailability of moxidectin in dogs using a semi-simultaneous method: influence of lipid co-administration. J. Vet. Pharmacol. Ther. 30:375-380. (Pubitemid 47366601)
10. Rock, D. W., R. L. DeLay, and M. J. Gliddon. 2002. Chemistry, pharmacology and safety: moxidectin, p. 77-96. In J. Vercruysse and R. S. Rew (ed.), Macrocyclic lactones in antiparasitic therapy. CABI Publishing, New York, NY.
11. U.S. Food and Drug Administration. 2005. Guidance for industry: clinical lactation studies-study design, data analysis, and recommendations for labeling. U.S. Food and Drug Administration, Rockville, MD. http://www.fda.gov/downloads/ Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072097.pdf